Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer Available to Purchase

A recent article characterized dosing recommendations for cabozantinib in people living with HIV (PLWH) and cancer, a group that is often excluded from clinical trials. This study suggests cabozantinib is effective in cancers disproportionately impacting PLWH and has translational implications for the design of studies evaluating drug-drug interactions.

See related article by Haigentz et al., p. 5038